Two different experimental mRNA vaccines have ‘now shown remarkable effectiveness of about 95 percent in preventing COVID-19 infection in adults,’ stated the U.S. Food and Drug Administration (FDA) leadership on January 4, 2020.
Read More
-
-
COVID-19 Pandemic Challenges Osteoporosis Management
-
AstraZeneca, J&J Resume U.S. COVID-19 Vaccine Trials
-
Survival From COVID-19 High in Patients With Psoriasis
-
FDA Needs More Safety Data on COVID-19 Vaccines, Experts Say
